SCHEMBL4539478

SCHEMBL4539478

N/C(=C\S)c1ccc(N2CCCC2)c(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.45
CYP3A4 P08684 1/20 0.43
SLC9A1 P19634 1/20 0.43
CYP2C19 P33261 1/20 0.43
NOTUM Q6P988 1/20 0.43
RARA P10276 1/20 0.41
RARB P10826 1/20 0.41
RARG P13631 1/20 0.41
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4531746 0.99 TAAR1 (0.44) TAAR1CYP3A4SLC9A1CYP2C19NOTUM
SCHEMBL15075695 0.88 SMN1; SMN2 (0.51) CYP3A4SLC9A1CYP2C19NOTUMKDM4E
SCHEMBL1397423 0.84 ALDH1A1 (0.55) TAAR1CYP3A4SLC9A1CYP2C19KDM4E
SCHEMBL4524615 0.80 ALDH1A1 (0.58) KDM4EGAAHSD17B10POLBTDP1
SCHEMBL15384274 0.80 ALDH1A1 (0.58) KDM4EGAAHSD17B10POLBTDP1
SCHEMBL3526351 0.80 TTR (0.59) TAAR1RARARARBRARGKDM4E
SCHEMBL2776207 0.78 KDM4E (0.61) TAAR1RARARARBRARGKDM4E
SCHEMBL17386600 0.78 TAAR1 (0.56) TAAR1NOTUM
SCHEMBL30949180 0.78 TAAR1 (0.50) TAAR1NOTUM
SCHEMBL3643489 0.78 KDM4E (0.61) TAAR1RARARARBRARGKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 EP disclosed
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. (US) 2013-06-27 US disclosed
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS HYDRA BIOSCIENCES, INC. 2013-03-07 US disclosed
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 TAAR1 992/4885CYP3A4 2741/4885SLC9A1 2798/4885
US-20130165427-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES ELANE, CASP3, MMP8 TAAR1 992/4885CYP3A4 2741/4885SLC9A1 2798/4885
US-20130059869-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS TRPA1, TRPV1, TRPV3 TAAR1 447/4885CYP3A4 2805/4885SLC9A1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.